Neil Sankar

Neil Sankar received his MD degree from Bangalore university and internal medicine residency from Univ of West indies, Kingston, Jamaica and trained in UK and the caribbeans. He also holds a postgraduate degree in public health from Queensland University in Australia.

Dr. Sankar got his training in clinical research and tumor biology from NCI Bethesda Maryland and since has held Clinical development positions within leading Biotech/Pharma including Genentech, Medimmune, Pharmacyclics, FiveprimeTherapeutics, Portola, Loxo Oncology, Otsuka Pharmaceuticals ,Elevar therapeutics, Boston Biomedical, Effector therapeutics and Rhizen Pharmaceuticals to name a few.

Dr. Sankar is President and Chief Medical Officer of SwanBio, LLC, a business development consultancy firm that facilitates the translation of scientific discoveries into cancer therapeutics. Dr. Sankar has over 16 years of experience in life sciences clinical development, pipeline strategy, clinical safety, and pharmacovigilance. He has extensive experience in the application of US Food and Drug Administration regulations and the Good Clinical Practice guidelines set forth by the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. He has acted as Medical lead in numerous phase I, II and III clinical trials in the therapeutic area of oncology ranging from Solid tumors, connective tissue tumors to Hematological malignancies including, CLL/SLL , B cell lymphomas, T cell Lymphomas, Acute Myeloid Leukemia and Hodgkins Lymphoma. He is expert in providing global clinical development and regulatory strategies for therapeutic drugs and was instrumental in filing the New Drug Applications for the antibody-drug conjugate in Metastatic Breast cancer and the Bruton tyrosine kinase inhibitor in Mantle cell Lymphoma . Dr. Sankar has extensive experience in designing and deploying data capture tools that evaluate the efficacy and safety of clinical trials. He also has extensive experience as a member of drug safety committees and advisory boards of few companies including Leukemia Therapeutics and iNDX technology. Dr Sankar has also led or have been part of FDA/Regulatory Authority discussions for various Companies pursuing IND and NDA applications including Pre-IND and Pre-NDA F2F meetings.

Dr. Sankar is an active member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Hematology Association (EHA, Drug information association (DIA), the European society of clinical oncology (ESMO), American association for cancer research (AACR), Enterprising Pharmaceutical Professionals from the Indian Sub-Continent (EPPIC GLOBAL), Connective Tissue Oncology Society (CTOS), IACA and TiE Silicon Valley.